PDCD1 and head and neck squamous cell carcinoma: To confirm the predictive role of DRGs risk score in immune therapy response in clinical tissue samples of HNSCC, 36 advanced HNSCC patients receiving anti-PD-1/PD-L1 therapy were analyzed.